Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play Intracellular actions of PCSK9
Jan Albert Kuivenhoven Intracellular actions of PCSK9
Play Back to basics on cost-effectiveness
Anthony Wierzbicki Back to basics on cost-effectiveness
Play Where are we with CVD prevention guidelines?
Henry Ginsberg Where are we with CVD prevention guidelines?
Play Preventing cardiovascular disease: the value of early signs of cardiac injury
Chris Packard Preventing cardiovascular disease: the value of early signs of cardiac injury
Play What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Brian Ference What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Play Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Rodrigo Alonso Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Play Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Raul Santos Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Play Outcomes data are critical
Francois Mach Outcomes data are critical
Play Collaboration between patient associations and healthcare professionals is key
Gunnar Karlsson Collaboration between patient associations and healthcare professionals is key
Play Many key barriers are amenable to change; new strategies are needed
David Hare Many key barriers are amenable to change; new strategies are needed
Play What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
Play PCSK9 inhibitors: Who and when to treat?
Anthony Wierzbicki PCSK9 inhibitors: Who and when to treat?
Play Current status of IVUS studies of plaque burden: what next with GLAGOV?
Steve Nicholls Current status of IVUS studies of plaque burden: what next with GLAGOV?
Play PCSK9 inhibition at the limits
John Chapman PCSK9 inhibition at the limits
Play How does PCSK9 inhibition influence cholesterol metabolism in humans?
Bo Angelin How does PCSK9 inhibition influence cholesterol metabolism in humans?
Play PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value
PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value
Play Lipoprotein-associated PCSK9: Physiological implications?
Sergio Fazio Lipoprotein-associated PCSK9: Physiological implications?
Play Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?
Chris Packard Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?
Play ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update
Jan Boren ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update
Play Innovative PCSK9-targeted therapeutics: siRNA
Steve Nicholls Innovative PCSK9-targeted therapeutics: siRNA